Retrospective analyses of acenocoumarol doses and bleeding complications in patients with wild type or variant cytochrome P450 CYP2C9 alleles [6]

Thrombosis and Haemostasis

Volumn 93, Issue 2, 2005, Pages 396-397

  Mark, Laszlo ^a   Marki Zay, Janos ^a   Paragh, Gÿorgy ^b   Katona, Andras ^a  

^a Pandy Kalman Bekes County Hospital   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; CYTOCHROME P450 2C9;

ALLELE; ANTICOAGULATION; BLEEDING; CORRELATION FUNCTION; DOSE RESPONSE; FOLLOW UP; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HUMAN; INCIDENCE; LETTER; PHARMACODYNAMICS; PHENOTYPE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK REDUCTION; STATISTICAL SIGNIFICANCE; WILD TYPE;

EID: 13844297738     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1616248     Document Type: Letter

References (4)

1. Visser LE, van Schaik RH, van Vliet M, et al. The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Thromb Haemost 2004; 92: 61-6.
2. Schalekamp T, van Geest-Daalderop JHH, de Vries-Goldschmeding H, et al. Acenocoumarol stabilization is delayed in CYP2C9*3 carriers. Clin Pharmacol Ther 2004; 75: 394-402.
3. Morin S, Bodin L, Loriot M-A, et al. Pharmacogenetics of acenocoumarol pharmacodynamics. Clin Pharmacol Ther 2004; 75: 403-14.
4. Takahashi H, Wilkinson GR, Padrini R, et al. CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin: similarities yet differences. Clin Pharmacol Ther 2004; 75: 376-80.